Early Detection Research Network

Esophagus

Esophageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.
http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/48/71
Under Review
Two
p16, RUNX3, and TMEFF2 (HPP1) display increasing methylation frequencies in Barrett's esophagus versus esophageal adenocarcinoma. These markers are being further investigated for potential utility in screening Barrett's patients likely to develop esophageal adenocarcinoma.
075ce52b1cf34fe2879d50ab75fb70d1
no
no
Contents

There are currently no items in this folder.